The bacterial colonization in tunneled cuffed dialysis catheter and its effects on residual renal function in incident hemodialysis patients

Clinical and Experimental Nephrology

Volumn 20, Issue 2, 2016, Pages 294-301

  Kang, Jin Suk ^a   Jang, Hee Ryeong ^a   Lee, Jeong Eun ^a   Park, Young Joo ^a   Rhee, Harin ^a   Seong, Eun Young ^a   Kwak, Ihm Soo ^a   Kim, Il Young ^a   Lee, Dong Won ^a   Lee, Soo Bong ^a   Song, Sang Heon ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Bacterial colonization; Catheter related infection; Hemodialysis; Vascular access device

Indexed keywords

ADULT; ANURIA; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; DIALYSIS CATHETER; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; TELEPHONE INTERVIEW; TUNNELED CUFFED DIALYSIS CATHETER; URINE VOLUME; AGED; CATHETER; CATHETER INFECTION; CHRONIC KIDNEY FAILURE; COMPLICATION; DEVICES; EPIDEMIOLOGY; HEMODIALYSIS; KIDNEY FUNCTION TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; SOUTH KOREA; URINE;

ADULT; AGED; CATHETER-RELATED INFECTIONS; CATHETERS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL DIALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84938507439     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1148-5     Document Type: Article

References (50)

1. Sabry AA, Elshafey EM, Alsaran K, Shalaby M, Alsherbeiny S, Abdelkader M. The level of C-reactive protein in chronic hemodialysis patients: a comparative study between patients with noninfected catheters and arteriovenous fistula in two large Gulf hemodialysis centers. Hemodial Int. 2014;18:674–9.
2. Goldstein SL, Ikizler TA, Zappitelli M, Silverstein DM, Ayus JC. Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int. 2009;76:1063–9.
3. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002;62:620–6.
4. Thomson PC, Stirling CM, Geddes CC, Morris ST, Mactier RA. Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death. QJM. 2007;100:415–22.
5. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis. 2006;47:469–77.
6. Jin DC, Han JS. Renal replacement therapy in Korea, 2012. Kidney Res Clin Pract. 2014;33:9–18.
7. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A. US renal data system 2013 annual data report: Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2014,2:216–228.
8. Goldstein S. Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis. 2006;48(Suppl 1):S2–90.
9. Boyce JM. Prevention of central line–associated bloodstream infections in hemodialysis patients. Infect Control. 2012;33:936–44.
10. Dittmer I, Sharp D, McNulty C, Williams A, Banks R. A prospective study of central venous hemodialysis catheter colonization and peripheral bacteremia. Clin Nephrol. 1999;51:34–9.
11. Fux CA, Uehlinger D, Bodmer T, Droz S, Zellweger C, Mühlemann K. Dynamics of hemodialysis catheter colonization by coagulase-negative staphylococci. Infect Control. 2005;26:567–74.
12. Branas P, Morales E, Rios F, Sanz F, Gutierrez E, Quintanilla N, et al. Usefulness of endoluminal catheter colonization surveillance cultures to reduce catheter-related bloodstream infections in hemodialysis. Am J Infect Control. 2014;42:1182–7.
13. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis. 1993;168:400–7.
14. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, et al. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hemodial Int. 2008;12:236–43.
15. Fontsere N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. Antimicrob Agents Chemother. 2014;58:4180–4.
16. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in Atherosclerosis. Circ J. 2010;74:213–20.
17. Raimann JG, Kitzler TM, Levin NW. Factors affecting loss of residual renal function(s) in dialysis. Contrib Nephrol. 2012;178:150–6.
18. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845–53.
19. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526–33.
20. Kim HW, Woo YS, Yang HN, Choi HM, Jo SK, Cho WY, et al. Primed monocytes: putative culprits of chronic low-grade inflammation and impaired innate immune responses in patients on hemodialysis. Clin Exp Nephrol. 2011;15:258–63.
21. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transpl. 2001;16:335–40.
22. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505–21.
23. Suresh DR, Silvia CRWD, Agarwal R. Biochemical markers of oxidative stress in predialytic chronic renal failure patients. Hong Kong J Nephrol. 2008;10:69–73.
24. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139–48.
25. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis. 2003;42:44–52.
26. McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial. 2010;23:449–51.
27. Lim WH, Kireta S, Leedham E, Russ GR, Coates PT. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int. 2007;72:1138–48.
28. Verkade MA, van Druningen CJ, Vaessen LM, Hesselink DA, Weimar W, Betjes MG. Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transpl. 2007;22:128–38.
29. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transpl. 2003;18:2067–73.
30. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85–90.
31. Bargman JM, Golper TA. The importance of residual renal function for patients on dialysis. Nephrol Dial Transpl. 2005;20:671–3.
32. Thomas J, Teitelbaum I. Preservation of residual renal function in dialysis patients. Adv Perit Dial. 2011;27:112–7.
33. Kim YB, Lee DW, An SJ, Jung YS, Lee SB, Kwak IS, et al. A study of central venous hemodialysis catheter colonization and peripheral bacteremia in patients undergoing hemodialysis. Korean J Med. 2001;61:121–6.
34. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999;34:1114–24.
35. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 2002;61:1136–42.
36. Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis. 2010;55:1060–8.
37. Power A, Duncan N, Singh SK, Brown W, Dalby E, Edwards C, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis. 2009;53:1034–41.
38. Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM, et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron. 2002;91:399–405.
39. de Freitas LW, Neto MM, Nascimento MM, Figueiredo JF. Bacterial colonization in hemodialysis temporary dual lumen catheters: a prospective study. Ren Fail. 2008;30:31–5.
40. Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transpl. 1999;14:1710–4.
41. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transpl. 1999;14:1956–60.
42. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can’t live without them. Kidney Int. 1999;56:1–17.
43. Toor MR, Singla A, Kim JK, Sumin X, DeVita MV, Michelis MF. Preventing the progression of chronic kidney disease: two case reports and review of the literature. Int Urol Nephrol. 2014;46:2167–74.
44. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter–related infections. Clin Infect Dis. 2002;35:1281–307.
45. Patel PR, Yi SH, Booth S, Bren V, Downham G, Hess S, et al. Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis. 2013;62:322–30.
46. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004;44:779–91.
47. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis. 2003;36:1539–44.
48. Onder AM, Chandar J, Billings A, Simon N, Gonzalez J, Francoeur D, et al. Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks. Pediatr Nephrol. 2009;24:2233–43.
49. Venditto M, Du Montcel ST, Robert J, Trystam D, Dighiero J, Hue D, et al. Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46 % versus heparin/gentamicin. Blood Purif. 2010;29:268–73.
50. Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist. 2014;7:343–63.